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Abstract: Melatonin is a multifaceted hormone which rises upon the onset of darkness. Pineal synthesis
of melatonin is known to be disturbed in patients with end-stage renal disease, but it is not known if its
production is restored to normal after successful renal transplantation. We hypothesized that urinary
excretion of 6-sulfatoxymelatonin, the major metabolite of melatonin, is lower in renal transplant
recipients (RTRs) compared to healthy controls and that this is associated with excess mortality.
Urinary 6-sulfatoxymelatonin was measured via LC-MS/MS in 701 stable outpatient RTRs and 285
healthy controls. Median urinary 6-sulfatoxymelatonin in RTR was 13.2 nmol/24 h, which was
47% lower than in healthy controls. Urinary 6-sufatoxymelatonin appeared undetectable in the
majority of 36 RTRs with diabetic nephropathy as primary renal disease. Therefore, this subgroup
was excluded from further analyses. Of the remaining 665 RTRs, during 5.4 years of follow-up, 110
RTRs died, of whom 38 died due to a cardiovascular cause. In Cox-regression analyses, urinary
6-sulfatoxymelatonin was significantly associated with all-cause mortality (0.60 (0.44–0.81), p = 0.001)
and cardiovascular mortality (0.49 (0.29–0.84), p = 0.009), independent of conventional risk factors
and kidney function parameters. Based on these results, evaluation and management of melatonin
metabolism could be considered for improvement of long-term outcomes in RTRs.
Keywords: 6-Sulfatoxymelatonin; Melatonin; Kidney Transplantation; Urinary Excretion; LC-MS/MS
1. Introduction
Many patients with end-stage renal disease (ESRD) experience sleep-related problems.
Although renal transplantation is the preferred treatment for end-stage renal failure, the quality
of sleep in these patients remains lower compared to the general population [1]. A combination of
factors, including chronic treatment with immunosuppressive medication, comorbidities, depression,
and stress have been indicated to adversely affect the quality of sleep in renal transplant recipients
(RTRs) [2,3]. Importantly, poor sleep quality has been implicated as a contributor to poor long-term
outcomes and premature mortality in patients with chronic kidney disease [4,5].
Melatonin is a multifaceted hormone that rises upon the onset of darkness. Melatonin is
synthesized from tryptophan and serotonin in the pineal gland. Melatonin present in the circulation
plays a vital role in the circadian rhythm and has been associated with the sleep–wake cycle [6,7].
After entering systemic circulation, where melatonin exerts its multiple functions via G protein-coupled
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melatonin-receptors, melatonin is metabolized by the liver, where approximately 90% of melatonin is
hydroxylated and subsequently conjugated to form 6-sulfatoxymelatonin (6-SM), which is excreted
in the urine [8,9]. The 24 h urinary 6-SM excretion therefore provides an integrated measurement of
melatonin production in circulation over a day [10].
Melatonin production has been shown to be severely disturbed in patients with ESRD [11]. It is not
known whether pineal melatonin production is restored to normal after successful renal transplantation.
Since poor sleep quality has been associated with poor long-term outcomes and mortality in patients
with chronic kidney disease, we hypothesized that low endogenous melatonin production in RTRs is
associated with increased risk for mortality in these patients. We therefore aimed to compare 24 h
urinary 6-SM excretion between RTRs and healthy controls and to prospectively analyse the association
of 24 h urinary 6-SM levels with mortality in a large cohort of stable outpatient RTRs, making use of an
existing biobank. In these latter analyses, diabetes, in particular diabetic nephropathy, and the use of
beta-blockers were of particular interest, because both have been reported to be associated with low
endogenous melatonin synthesis and low urinary 6-SM excretion [12–15].
2. Materials and Methods
2.1. Study Population
For this study, we performed post-hoc analysis on an existing biobank underlying this prospective
cohort study. The cohort comprised RTRs with a graft that had been stable for at least one year.
The RTRs visited the outpatient clinic of the University Medical Center Groningen (UMCG), the
Netherlands, between November 2008 and June 2010, as described previously [16]. Out of the 817
eligible RTRs, 707 were included and written informed consents were obtained. The median time after
transplantation was 5.5 (interquartile range (IQR) 2.0–12.1) years (transplant vintage). For 701 out
of the 707 RTRs, 24 h urine samples were available for 6-SM analysis. As control group, 285 healthy
controls were included. These controls were kidney donors who participated in a screening program
and were included in another cohort. None of the donors had a history of kidney disease, diabetes, or
cardiovascular disease. The Medical Ethical Committee of the UMCG approved the study protocol
(METc 2008/186) according to the principals of the Declaration of Helsinki.
2.2. Data and sample collection
Fasting blood samples of RTRs were drawn in the morning on the day following collection of 24 h
urine samples. Routine laboratory analysis in plasma and urine were performed shortly after collection,
according to standard laboratory procedures. Plasma and urine samples were stored at −80 ◦C.
Detailed information on the laboratory measurements in this RTR-cohort is described elsewhere [17].
The UMCG renal transplantation database provided information such as date of transplantation,
primary renal disease, history of acute rejection, dialysis vintage, and donor status. Data on causes
of death were obtained from patients’ records. The glomerular filtration rate (eGFR) was estimated
using an equation that included both creatinine and cystatin C [18]. The use of medication and vitamin
supplementation were recorded according to patients’ medical records.
2.3. Urinary 6-SM Laboratory Measurements
6-SM was measured in 24 h urine samples via isotope dilution liquid chromatography (Pursuit
XRS Diphenyl column, Agilent, Santa Clara, CA, USA) combined with tandem mass spectrometry
(SPE-LC-MS/MS) (Symbiosis™ Pharma system, Spark Holland, Emmen, the Netherlands and XEVO
TQS, Waters, Milford, MA, USA). The urine samples were not stabilized and the pH was not altered.
6-SM-d4 (CacheSyn Inc., Mississauga, Canada) was used as the internal standard. The inter-assay
coefficient of variation was <5.4%. The lower limit of quantitation (LLOQ) for 6-SM in urine was
0.20 nmol/L. If a urinary 6-SM value was below the LLOQ, the value was set to 0.20 nmol/L to allow
for inclusion of these subjects in further analysis.
J. Clin. Med. 2020, 9, 525 3 of 12
2.4. Clinical Endpoints
The primary endpoint of this study was all-cause mortality related to 24 h urinary 6-SM output in
RTRs. A secondary endpoint was cardiovascular mortality. Cardiovascular mortality included death
by cerebrovascular disease, ischemic heart disease, heart failure, or sudden cardiac death according
to the International Classification of Diseases, 9th revision (ICD-9), codes 410–447. Endpoints were
recorded until the end of September 2015 [19].
2.5. Statistical Analysis
Statistical analyses were performed with SPSS statistics version 22.0 (IBM, Armonk, NY, USA).
The data are presented as mean ± standard deviation (SD), as median (IQR) or as number (percentage,
n%). A p-value < 0.05 was considered statistically significant. Normal distribution was tested with
histograms and probability plots. Non-normally distributed data were transformed to 10log, in order
to meet the assumptions for linear regression analysis.
Differences between RTRs and healthy controls were determined using univariable regression
analyses. Since 24 h urinary 6-SM excretion may be confounded by age, sex, and eGFR as
an indication for kidney function, additional multivariable regression analyses were performed,
expressed as standardized β. Standardized β allows the comparison of variables with different units,
since standardized β makes use of the SD. The higher the standardized β, the stronger the effect.
As the presence of diabetic nephropathy as primary renal disease and the use of beta-blockers
have been reported to be associated with particularly low urinary 6-SM excretion [12–15], we separately
evaluated whether they were associated with a particularly high frequency of undetectable urinary 6-SM
concentrations, which might preclude further analyses on urinary 6-SM excretion in these subgroups.
The RTR population was divided into tertiles of 24 h urinary 6-SM excretion. To identify
associations of urinary 6-SM excretion with baseline variables, univariable linear regression analyses
were performed (p-trend). To identify independent determinants of 24 h urinary 6-SM excretion,
multivariable linear regression analyses were performed. Multivariable linear regression models
were constructed using backward selection, and included variables that were associated with urinary
6-SM excretion in the univariable analysis with a p-value of <0.20. For related variables, the variable
with the strongest association was included in the analysis. All variables were entered into the linear
regression model. The variable with the highest p-value was excluded and the regression analysis was
performed again without this variable. This was repeated until all the variables had a p-value below
the significance level of 0.05.
To test whether urinary 6-SM excretion was associated with all-cause and cardiovascular mortality,
the tertiles of urinary 6-SM excretion were analyzed by Kaplan–Meier analysis with log-rank testing.
To report the number of RTRs still at risk of an event at the follow-up time-points of 0, 1, 2, 3, 4, 5,
and 6 years, “life tables” were run. Subsequently, Cox proportional hazard regression analyses, with
adjustment for potential confounders, were performed on the continuous variable of urinary 6-SM
excretion, including the tertiles. The first tertile served as the reference group, and the hazard ratio
(HR) was therefore set to 1. An HR lower than the reference value of 1 indicated a poorer outcome
concerning mortality. Prospective associations were cumulatively adjusted for potential confounders
in five models, to avoid overfitting and to keep the number of predictors in proportion to the number
of events. Confounders adjusted for included age and sex (Model 2), waist circumference and smoking
(Model 3), diabetes and serum albumin (Model 4), and finally beta-blocker use, eGFR, acute rejection,
donor status (living or deceased), and proteinuria (Model 5). Proportionality of hazards was tested by
examining the Schoenfeld residuals.
3. Results
Baseline characteristics of the 701 RTRs and 285 healthy controls are shown in Table 1. Median
(IQR) 24 h urinary 6-SM excretion in RTRs was 13.2 nmol/24 h (3.5–31.2 nmol/24 h), which was 47%
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lower than in the healthy controls (24.9 (11.6–41.2) nmol/24 h). Of the RTR, 81 (12%) had urinary 6-SM
concentrations below the detection limits, compared to 3 (1%) in the healthy controls. In multivariable
linear regression analyses, the difference in urinary 6-SM excretion between RTRs and healthy controls
appeared to be independent of age and sex and partly independent of eGFR.






Model 1 Model 2 Model 3
6-SM (nmol/24 h) 24.9 (11.6–41.2)1 13.2 (3.5–31.2) −0.244 *** −0.276 *** −0.062 **
6-SM (nmol/L) 9.9 (4.5–17.9) 5.2 (1.5–12.7) −0.152 *** −0.180 *** −0.071 **
Urine volume (L) 2.5 (2.0–3.0) 2.4 (1.9–2.8) −0.069 * −0.064 * 0.000
Undetectable 6-SM levels, n% 3 (1) 81 (12) 0.169 *** 0.178 *** 0.024
Age, years 53.3 ± 10.82 53.0 ± 12.7 −0.019
Male sex, n% 135 (47) 399 (57) −0.089**
eGFR, mL/min per 1.73 m2 90.9 ± 14.1 45.0 ± 18.7 −0.749 *** −0.758 ***
Total cholesterol, nmol/L 5.4 ± 1.1 5.1 ± 1.1 −0.106 ** −0.095 ** −0.064 **
Waist-circumference, cm 91.1 ± 10.1 98.6 ± 14.7 0.216 *** 0.220 *** 0.066 **
hsCRP, mg/L 1.1 (0.6–2.3) 1.6 (0.7–4.6) 0.113 *** 0.133 *** −0.002
Serum glucose, mmol/L 5.4 ± 0.6 5.7 ± 1.8 0.060 0.056 0.046 *
HbA1c, % 5.6 ± 0.3 6.0 ± 0.8 0.245 *** 0.258 *** 0.135 ***
PTH, pmol/L 3.3 (2.6–4.2) 8.9 (5.9–14.7) 0.552 *** 0.553 *** 0.192 ***
Beta-blocker use, n% 13 (5) 448 (64) 0.506 *** 0.509 *** 0.217 ***
1 Differences between groups were analyzed with univariable and multivariable linear regression analyses, for which
the standardized ßs are shown (* p < 0.05, ** p < 0.01, *** p < 0.001). Model 1 was a crude model, Model 2 was
adjusted for age and sex. Model 3 was adjusted for Model 2 and eGFR; 1Median (IQR); 2Mean ± SD. Abbreviations:
6-SM: 6-sulfatoxymelatonin; eGFR: estimated glomerular filtration rate; HbA1c: glycated hemoglobin; hsCRP:
high-sensitivity C-reactive protein; PTH: parathyroid hormone.
In the 36 RTRs with diabetic nephropathy as primary renal disease, the frequency of urinary
6-SM below the detection limit was 22 (61%), which was much higher than the frequency of 59 (9%) in
the rest of the RTRs. In the 422 RTRs that were using beta-blockers, the frequency of urinary 6-SM
below the detection limit was 55 (13%), which was higher than the frequency of 4 (1.6%) in the rest
of the RTRs. Because of the very high frequency of urinary 6-SM concentrations below the detection
limit, subjects with diabetic nephropathy were excluded from further analyses. Baseline characteristics
of the remaining 665 RTRs, presented according to tertiles of urinary 6-SM excretion, are shown in
Table 2. RTRs in the highest tertile of urinary 6-SM excretion were significantly younger, had a lower
waist circumference, experienced less acute rejection, had higher eGFR levels as a parameter for
kidney function, and had a lower prevalence of diabetes, also marked by lower serum glucose and
HbA1c levels, and less use of antidiabetic medication. Furthermore, the urinary 6-SM excretion levels
were significantly lower in RTRs who had received a kidney from a deceased donor compared to a
living donor (10.2 nmol/24 h (IQR 3.2–25.8 nmol/24 h) and 20.5 nmol/24 h (IQR 9.1–39.2 nmol/24 h)
respectively, p < 0.001, Mann–Whitney U test).
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Table 2. Baseline patient characteristics of the stable RTRs (without diabetic nephropathy) presented as










6-SM (nmol/24 h) * 14.3 (4.4–31.6) <7.0 7.0–23.7 >23.7 <0.001
Demographics
Age, years 52.8 ± 12.9 58.9 ± 9.9 52.4 ± 12.0 47.0 ± 13.7 <0.001
Male sex (n%) 376 (57) 119 (54) 143 (64) 114 (51) 0.96
6-SM (nmol/L) 5.9 (1.8–13.1) 0.97 (0.2–1.8) 5.9 (4.0–8.3) 18.3 (12.2–27.9) <0.001
Urine volume (L) 2.4 (1.9–2.8) 2.4 (1.9–2.8) 2.4 (1.9–2.8) 2.4 (1.9–2.8) 0.97
Undetectable 6-SM levels (n%) 59 (9) 59 (27) 0 (0) 0 (0) <0.001
Current smoker (n%) 81 (12) 24 (11) 35 (16) 22 (10) 0.95
BMI (kg/m2) 26.6 ± 4.7 27.0 ± 4.6 26.3 ± 4.4 26.5 ± 5.0 0.09
Alcohol intake (g/d) 3.0 (0.04–11.5) 2.02 (0.03–13.2) 3.49 (0.05–12.1) 3.08 (0.05–9.9) 0.55
Waist circumference (cm) 98.3 ± 14.4 99.6 ± 14.4 99.5 ± 14.1 95.8 ± 14.3 0.004
Body surface area (m2) 1.94 ± 0.22 1.91 ± 0.21 1.96 ± 0.22 19.4 ± 0.22 0.47
Systolic BP (mmHG) 135.3 ± 17.3 136.8 ± 17.5 134.9 ± 18.3 134.2 ± 16.0 0.16
Diastolic BP (mmHG) 82.3 ± 10.9 81.8 ± 10.0 83.1 ± 12.0 82.3 ± 10.8 0.39
History of CVD (n%) 84 (13) 30 (14) 29 (13) 25 (11) 0.44
Renal transplantation
Transplant vintage (years) 5.5 (2.0–12.1) 6.9 (3.2–14.0) 5.4 (1.5–12.3) 4.9 (1.4–10.4) 0.005
Living donor (n%) 228 (34) 45 (20) 82 (37) 101 (45) <0.001
Acute rejection (n%) 172 (26) 63 (29) 67 (30) 42 (19) 0.002
Cold ischemia time (hours) 14.5 (2.6–21.0) 16.2 (8.2–22.5) 12.4 (2.6–20.9) 10.7 (2.4–19.6) <0.001
Primary renal disease (n%)
Primary glomerular disease 197 (30) 61 (28) 75 (34) 61 (27) 0.52
Glomerulonephritis 52 (8) 20 (9) 12 (5) 20 (9) 0.55
Tubulointerstitial disease 84 (13) 22 (10) 24 (11) 38 (17) 0.10
Polycystic renal disease 145 (22) 48 (22) 55 (25) 42 (19) 0.56
Dysplasia and hypoplasia 28 (4) 9 (4) 7 (3) 12 (5) 0.56
Renovascular disease 40 (6) 12 (5) 14 (6) 14 (6) 0.84
Other or unknown cause 118 (18) 48 (22) 35 (16) 35 (16) 0.12
Laboratory measurements
eGFR (mL/min per 1.73 m2) 45.4 ± 18.8 41.3 ± 19.5 46.8 ± 17.8 46.8 ± 18.3 <0.001
Serum albumin (g/L) 43.1 ± 3.0 42.7± 2.9 43.0 ± 3.0 43.5 ± 2.9 0.001
Proteinuria (n%) 136 (20) 50 (23) 45 (20) 41 (18) 0.07
NT-pro BNP (ng/L) 243 (103–594) 434 (182–1120) 113 (105–432) 143 (67–363) 0.04
Total cholesterol (mmol/L) 5.1 ± 1.1 5.3 ± 1.2 5.0 ± 1.1 5.1 ± 1.0 0.05
LDL cholesterol (mmol/L) 3.0 ± 0.93 3.1 ± 1.0 2.9 ± 0.94 3.0 ± 0.86 0.10
HDL cholesterol (mmol/L) 1.3 (1.1–1.6) 1.3 (1.1–1.6) 1.3 (1.0–1.6) 1.3 (1.1–1.7) 0.37
hsCRP (mg/L) 1.6 (0.7–4.6) 2.1 (0.8–5.1) 1.5 (0.6–4.5) 1.5 (0.7–4.5) 0.009
Serum calcium (mmol/L) 2.4 ± 0.15 2.4 ± 0.15 2.4 ± 0.15 2.4 ± 0.15 0.49
PTH (pmol/L) 8.9 (5.8–14.6) 9.5 (6.3–16.5) 8.9 (5.6–15.3) 8.5 (5.5–13.7) 0.29
Medication
Antihypertensiva
Beta-blockers (n%) 422 (63) 183 (83) 140 (63) 99 (45) <0.001
Calcium antagonists (n%) 159 (24) 61 (28) 53 (24) 45 (20) 0.08
ACE inhibitors (n%) 218 (33) 66 (30) 80 (36) 72 (32) 0.51
Immunosuppressive therapy
Prednisolone (n%) 658 (99) 218 (99) 218 (98) 222 (100) 0.14
Calcineurin inhibitor (n%) 370 (56) 120 (54) 125 (56) 125 (56) 0.90
Proliferation inhibitors (n%) 555 (83) 177 (80) 189 (85) 189 (85) 0.49
mTOR inhibitors (n%) 24 (4) 10 (5) 6 (3) 8 (4) 0.66
Proton pump inhibitors (n%) 323 (49) 125 (57) 105 (47) 93 (42) 0.02
Diabetes parameters
Serum glucose (mmol/L) 5.2 (4.8–6.0) 5.3 (4.8–6.0) 5.3 (4.8–6.1) 5.1 (4.7–5.8) 0.03
HbA1c (%) 5.9 ± 0.8 6.0 ± 0.8 5.9 ± 0.8 5.8 ± 0.7 0.02
Current diabetes (n%) 146 (22) 62 (28) 47 (21) 37 (17) 0.02
Pre-transplant diabetes (n%) 13 (2) 4 (2) 2 (1) 7 (3) 0.35
Antidiabetica (n%) 87 (13) 40 (18) 31 (14) 16 (7) 0.002
1 Data are presented as mean ± SD, percentage (n%) or median (IQR). The p-values (p for trend) were obtained
by linear regression analyses. Abbreviations: 6-SM: 6-sulfatoxymelatonin; ACE: angiotensin-converting enzyme;
BMI: body mass index; BP: blood pressure; CVD: cardiovascular disease; eGFR: estimated glomerular filtration
rate; HbA1c: glycated hemoglobin; HDL: high-density lipoprotein; hsCRP: high-sensitivity C-reactive protein; LDL:
low-density lipoprotein; mTOR: mechanistic target of rapamycin; NT-pro BNP: N-terminal prohormone of brain
natriuretic peptide; PTH: parathyroid hormone.
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For the assessment of independent associations of urinary 6-SM excretion parameters, multivariable
linear regression analysis with backward elimination was performed. It was found that age, history of
acute rejection, and beta-blocker use were inversely associated with urinary 6-SM excretion, whereas
living donor status was positively associated, as shown in Table 3.
Table 3. Univariable and multivariable associations of 6-sulfatoxymelatonin excretion with clinical
parameters in 665 RTRs (without diabetic nephropathy) 1.
Urinary 6-Sulfatoxymelatonin Excretion
Univariable Multivariable
Standardized ß p-Value Standardized ß p-Value
Demographics
Age (years) −0.351 <0.001 −0.282 <0.001
Sex −0.002 0.96
Waist circumference (cm) −0.115 0.004
SBP (mmHG) –0.055 0.16
Renal transplantation
Transplant vintage (years) −0.110 0.005
Living donor 0.224 <0.001 0.130 <0.001
Acute rejection −0.118 0.002 −0.082 0.02
Cold ischemia time, hours −0.182 <0.001
Primary renal disease
Tubulointerstitial disease 0.065 0.10
Other or unknown cause –0.060 0.12
Laboratory measurements
eGFR (mL/min per 1.73 m2) 0.153 <0.001
Serum albumin (g/L) 0.130 0.001
Proteinuria (n%) −0.070 0.07
NT-pro BNP (ng/L) −0.081 0.04
Total cholesterol (nmol/L) −0.077 0.05
hsCRP (mg/L) –0.102 0.009
Medication
Beta-blockers −0.324 <0.001 −0.264 <0.001
Prednisolone (mg/d) 0.057 0.14
Proton-pump inhibitors –0.094 0.02
Diabetes parameters
Serum glucose (mmol/L) −0.087 0.03
HbA1c (%) −0.093 0.02
Current diabetes −0.089 0.02
Antidiabetica –0.118 0.002
1 Multivariable linear regression analysis using backward selection (pout > 0.05). Abbreviations: CVD: cardiovascular
disease; eGFR: estimated glomerular filtration rate; HbA1c: glycated hemoglobin; hsCRP: high-sensitivity C-reactive
protein; NT-pro BNP: N-terminal prohormone of brain natriuretic peptide; PTH: parathyroid hormone; SBP: systolic
blood pressure.
After a median follow-up of 5.4 (4.8–6.1) years, 110 out of 665 RTRs had died (17%), of whom 38
(35%) were due to a cardiovascular cause, including cerebrovascular disease, ischemic heart disease,
heart failure, and sudden cardiac death. Kaplan–Meier analysis showed increased risk of all-cause
mortality with decreasing tertiles of urinary 6-SM excretion, as shown in Figure 1. Similar results were
observed for cardiovascular mortality, both with log-rank p < 0.001.
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Figure 1. Kaplan–Meier curves for mortality of RTRs according to the tertiles of urinary 6-
sulfatoxymelatonin excretion. (A) All-cause mortality, and (B) cardiovascular mortality. Below the 
horizontal axis, the numbers of patients still at risk of an event at the follow-up time-points 0, 1, 2, 3, 
4, 5, and 6 years are shown. Abbreviations: 6-SM: 6-sulfatoxymelatonin, CVD: cardiovascular disease. 
Cox regression analyses revealed that urinary 6-SM excretion, as a continuous variable, was 
significantly inversely associated with all-cause mortality (HR (95% confidence interval (CI)) = 0.60 
(0.44–0.81), p = 0.001), independent of potential confounders, including age, sex, waist circumference, 
smoking, diabetes, serum albumin, eGFR, acute rejection, proteinuria, donor status, and beta-blocker 
use, as shown in Table 4. Analysis according to the tertiles of urinary 6-SM excretion revealed that 
RTRs in the lowest tertile (i.e., lowest urinary 6-SM levels) had a higher risk of mortality, compared 
to RTRs in the intermediate (HR (95% CI) = 0.80 (0.51–1.26)) and highest tertiles (HR (95% CI) = 0.43 
(0.24–0.77)). 
Cox regression analysis of urinary 6-SM excretion with cardiovascular mortality also displayed 
a significant association, independent of the potential confounders, (HR (95% CI) = 0.49 (0.29–0.84), p 
= 0.009). Analysis of the tertiles of urinary 6-SM excretion demonstrated an increased cardiovascular-
related mortality risk of RTRs in the lowest tertile compared to the middle tertile (HR (95% CI) = 0.70 
(0.33–1.51)) and highest tertile (HR (95% CI) = 0.27 (0.09–0.78)), in line with what was found for all-
cause mortality. 
Table 4. Cox proportional hazards regression analysis for the association of 6-sulfatoxymelatonin 
with all-cause and cardiovascular mortality in RTRs (without diabetic nephropathy) 1. 
 Tertile 1  Tertile 2  Tertile 3 Overall 
 HR (95% CI) HR (95% CI) p-Value HR (95% CI) p-Value HR (95% CI) p-Value 
All-cause 
mortalitya 
       
Model 1 c 1.0 (Ref) 0.59 (0.39–0.90) 0.01 0.27 (0.16–0.46) <0.001 0.45 (0.34–0.59) <0.001 
Model 2 d 1.0 (Ref) 0.81 (0.53–1.24) 0.34 0.45 (0.26–0.78) 0.004 0.60 (0.45–0.80)  0.001 
Model 3 e 1.0 (Ref) 0.76 (0.50–1.12) 0.20 0.44 (0.25–0.76) 0.003 0.60 (0.45–0.79) <0.001 
Model 4 f 1.0 (Ref) 0.73 (0.48–1.12) 0.15 0.42 (0.24–0.73) 0.002 0.58 (0.44–0.77) <0.001 
Figure 1. Kaplan–Meier curves for mortality of RTRs according to the tertiles of urinary
6-sulfatoxymelatonin excretion. (A) All-cause mortality, and (B) cardiovascular mortality. Below the
horizontal axis, the numbers of patients still at risk of an event at the follow-up time-points 0, 1, 2, 3, 4,
5, and 6 years are shown. Abbreviations: 6-SM: 6-sulfatoxymelatonin, CVD: cardiovascular disease.
Cox regression analyses revealed that urinary 6-SM excretion, as a continuous variable,
was significantly inversely associated with all-cause mortality (HR (95% confidence interval (CI)) = 0.60
(0.44–0.81), p = 0.001), independent of potential confounders, including age, sex, waist circumference,
smoking, diabetes, serum albumin, eGFR, acute rejection, proteinuria, donor status, and beta-blocker
use, as shown in Table 4. Analysis according to the tertiles of urinary 6-SM excretion revealed that
RTRs in the lowest tertile (i.e., lowest urinary 6-SM levels) had a higher risk of mortality, compared to
RTRs in the intermediate (HR (95% CI) = 0.80 (0.51–1.26)) and highest tertiles (HR (95% CI) = 0.43
(0.24–0.77)).
Table 4. Cox proportional hazards regression analysis for the association of 6-sulfatoxymelatonin with
all-cause and cardiovascular mortality in RTRs (without diabetic nephropathy) 1.
Tertile 1 Tertile 2 Tertile 3 Overall
HR (95% CI) HR (95% CI) p-Value HR (95% CI) p-Value HR (95% CI) p-Value
All-cause
mortality a
Model 1 c 1.0 (Ref) 0.59 (0.39–0.90) 0.01 0.27 (0.16–0.46) <0.001 0.45 (0.34–0.59) <0.001
Model 2 d 1.0 (Ref) 0.81 (0.53–1.24) 0.34 0.45 (0.26–0.78) 0.004 0.60 (0.45–0.80) 0.001
Model 3 e 1.0 (Ref) 0.76 (0.50–1.12) 0.20 0.44 (0.25–0.76) 0.003 0.60 (0.45–0.79) <0.001
Model 4 f 1.0 (Ref) 0.73 (0.48–1.12) 0.15 0.42 (0.24–0.73) 0.002 0.58 (0.44–0.77) <0.001
Model 5 g 1.0 (Ref) 0.80 (0.51–1.26) 0.34 0.43 (0.24–0.77) 0.004 0.60 (0.44–0.81) 0.001
Cardiovascular
mortality b
Model 1 c 1.0 (Ref) 0.61 (0.30–1.21) 0.16 0.21 (0.08–0.57) 0.002 0.42 (0.27–0.67) <0.001
Model 2 d 1.0 (Ref) 0.78 (0.38–1.58) 0.48 0.33 (0.12–0.90) 0.03 0.52 (0.32–0.86) 0.01
Model 3 e 1.0 (Ref) 0.69 (0.34–1.41) 0.31 0.32 (0.12–0.88) 0.03 0.52 (0.32–0.86) 0.01
Model 4 f 1.0 (Ref) 0.63 (0.31–1.29) 0.20 0.28 (0.10–0.76) 0.01 0.48 (0.29–0.78) 0.003
Model 5 g 1.0 (Ref) 0.70 (0.33–1.51) 0.37 0.27 (0.09–0.78) 0.01 0.49 (0.29–0.84) 0.009
1 Data are presented as hazard ratio (HR) with the 95% CI and p-values according to the tertiles of 6-SM and the
continuous data. a Nevents/Ntotal = 110/665; b Nevents/Ntotal = 38/665; c Model 1: crude; d Model 2: adjusted for
age, sex; e Model 3: waist circumference, smoking; f Model 4: current diabetes, serum albumin; g Model 5: eGFR,
acute rejection, proteinuria, living donor, beta-blocker. Abbreviations: 6-SM: 6-sulfatoxymelatonin; CI: confidence
interval; HR: hazard ratio.
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Cox regression analysis of urinary 6-SM excretion with cardiovascular mortality also displayed
a significant association, independent of the potential confounders, (HR (95% CI) = 0.49 (0.29–0.84),
p = 0.009). Analysis of the tertiles of urinary 6-SM excretion demonstrated an increased
cardiovascular-related mortality risk of RTRs in the lowest tertile compared to the middle tertile (HR
(95% CI) = 0.70 (0.33–1.51)) and highest tertile (HR (95% CI) = 0.27 (0.09–0.78)), in line with what was
found for all-cause mortality.
4. Discussion
In this study, we found that 24 h urinary 6-SM excretion, measured with a reliable isotope dilution
LC-MS/MS method, was much lower in stable outpatient RTRs than in healthy controls and that
low urinary 6-SM excretion was significantly and independently associated with increased risk of
premature mortality, particularly cardiovascular mortality.
The role of melatonin during (end-stage) kidney disease and transplantation is increasingly being
studied [3,11]. In the case of renal transplantation, a study by Russcher et al. showed that melatonin
levels measured in saliva did not improve 3 months after kidney transplantation, and concluded that
the time-span after transplantation was too short to see a possible improvement [20]. Burkhalter et
al. also measured saliva melatonin in 29 stable RTRs more than 1 year post-transplantation. In these
RTRs with sleep–wake disturbances, they found low melatonin levels, mainly in the RTRs without
dim-light melatonin onset, and this was related to health impairment in this group [21]. In line with
our study results, they found a high percentage of RTRs with fairly low to no melatonin production.
These studies showed that restoration of melatonin levels does not occur shortly after transplantation,
and our study showed that after a median of 5.5 years following transplantation, the levels are still
clearly reduced compared to healthy controls.
Lower urinary 6-SM levels in RTRs compared to healthy controls seem to be partly explained
by kidney function, as shown by multivariable linear regression analyses. Besides decreased kidney
function, several factors could result in reduced urinary 6-SM in the RTR population. One factor
known to reduce melatonin levels is pineal calcification, relatively common with increasing age [22].
A study by Kunz et al. showed reduced urinary 6-SM excretion with increasing pineal calcification [23].
As expected, our RTRs had clearly increased levels of parathyroid hormone (PTH). PTH results in
increased mobilization of calcium from bones and promotes reabsorption of calcium in the kidneys [24].
Combined with the reduced renal function in RTRs, less calcium is excreted via the urine; it can then
precipitate in soft tissue where it can cause vascular calcification [25,26]. It could be possible that the
pineal gland is affected by the calcium deposit. However not much is known yet about the link between
PTH and pineal calcification. Another important, extrinsic factor that could influence melatonin
levels is the use of medication, and in particular beta-blockers [12,27]. Beta-blockers reduce melatonin
production by blocking the adrenergic beta-1 receptor [12]. Inhibition of this receptor prevents the
activation of serotonin N-acetyltransferase, necessary for the conversion of serotonin to melatonin.
Of the RTRs in this study, 63% used beta-blockers to control hypertension. The cross-sectional data
of RTRs on beta-blockers showed significantly lower levels of urinary 6-SM, however, correction for
beta-blockers as a potential confounder in prospective analysis did not influence the association of
urinary 6-SM excretion with mortality. Additionally, in our cohort of stable RTRs, it was found that
patients who had received a kidney from a living donor had higher urinary 6-SM levels compared to
patients that had received a kidney from a deceased donor. The waiting time for a kidney from a living
donor is usually shorter, generally resulting in considerably less advanced kidney disease and less
time spent on dialysis or preemptive transplantation [28,29]. In line with this, we found a strongly
significant association between higher cold ischemia time and lower urinary 6-SM excretion. Lastly,
multiple studies have demonstrated that RTRs experience poor sleep quality, and a high prevalence
of insomnia is found in this population [1,30–32]. Melatonin secretion is an important marker for
the circadian rhythm and it signals the “biological night”, causing the onset of sleep in humans [8].
The reduced levels of melatonin measured in the RTRs in this study could be influenced by or cause
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the sleep-related problems. This was recognized by the study of Russcher et al. mentioned earlier,
where the authors did not find improved sleep quality and melatonin levels after renal transplantation,
despite improved renal function [20].
We found that RTRs with diabetic nephropathy as primary renal disease showed clearly reduced to
no detectable urinary 6-SM levels. Diabetes and diabetic complications, such as diabetic nephropathy,
are associated with the increased presence of oxidative stress after a persistent period of poor glucose
control [33,34]. Patients with diabetic nephropathy often experience serial problems affecting the eyes,
arteries, and peripheral nerves. Currently, transplantation is considered the preferred treatment for
patients with ESRD caused by diabetic nephropathy [35]. Why the RTRs with diabetic nephropathy
as primary renal disease have lower 6-SM compared to the total RTR population needs to be further
investigated. Potential mechanisms could include imbalance in the production of reactive oxygen
species, increased vascular calcification, retinopathy, or impaired glucose control. Systemic melatonin
synthesis is dependent on the light–dark signals transmitted via the retino-hypothalamic tract [8].
These signals might be absent in patients with severe retinopathy, possibly influencing their melatonin
levels [36,37]. One study showed that rats with diabetic nephropathy benefit from treatment with
melatonin, most likely via reduction of the oxidative stress, demonstrating a potentially important of
role melatonin in the treatment of RTRs with diabetic nephropathy as primary renal disease [38].
The present study showed that reduced urinary 6-SM excretion was associated with an increased
risk of all-cause mortality in RTRs independent of age, kidney function, and beta-blocker use. In addition
to all-cause mortality, this study showed that low urinary 6-SM levels were independently associated
with cardiovascular mortality. Cardiovascular disease is a major cause of death in RTRs, caused by
conventional risk factors such as hypertension, diabetes, and renal dysfunction [39]. Reduced urinary
6-SM excretion has been linked to coronary artery disease (CAD); the severity of CAD was negatively
associated with urinary 6-SM excretion [40]. Melatonin is known to influence the cardiovascular system
via both its antioxidant and anti-inflammatory activities [41]. In rats with renovascular hypertension,
the cardiac function improved after treatment with melatonin, implying a possible therapeutic role
of melatonin [42]. That melatonin could play a possible important role in kidney transplantation as
a therapeutic approach was also demonstrated in a study by Li et al. [43]. In this study, with rats, it
was shown that donor pre-conditioning with melatonin protected the kidney graft, likely through its
antioxidative properties, improving the survival.
Future investigations should focus on whether supplementation of melatonin in RTRs can prevent
the known circadian rhythm sleeping disorders and act as a possible cardiovascular protector by
lowering the oxidative stress. In line with this, it would be interesting to examine whether melatonin
supplementation affects the mortality rates in RTRs by means of a double-blind randomized control trial.
Some limitations of the study should be noted. The 24 h urine samples were collected just once,
and the conclusions are therefore based on a single measurement. Since the patients were carefully
instructed on how to collect the urine, over- and under-collections were unlikely, as previously tested
by sensitivity analysis in the same cohort [44]. An additional limitation of this study was the lack
of information on sleep reported by or monitored in the RTRs. Subsequently, there were no data
available on the use of sleep-related medication or the presence of sleeping disorders such as obstructive
sleep apnea syndrome. Even though many studies have shown a link between melatonin and sleep
disturbances, we were not able to examine this in our study, and this would a valuable addition for
future studies. Additionally, it would have been interesting to examine the association with mortality
in healthy individuals, with sufficient follow-up time to underline the findings in the present study.
This study could, for instance, be combined with individuals with and without sleep deprivation, to
emphasize the results of the current study possibly even more.
One of the major strengths of this study was the use of 24 h urine for 6-SM analysis, instead of using
plasma melatonin or saliva melatonin. Collection of 24 h urine provides insight over a whole day, rather
than at a single time-point, as is the case with plasma melatonin or saliva melatonin. This is particularly
of interest because melatonin production is influenced by the circadian rhythm. Furthermore, it has
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been shown that urinary melatonin levels are stable over time within an individual [45]. However, it is
important to realize that melatonin levels can be influenced to a certain degree by seasonal changes,
working night shifts, and the degree of exposure to artificial light [46,47]. Another strength of this study
was the use of LC-MS/MS to measure 6-SM. Compared to immunoassays, LC-MS/MS is more specific,
robust, and able to measure low concentrations of urinary 6-SM. Finally, this was an observational
study, and it is therefore possible that unmeasured or additional confounding variables might have
been present, despite the many potential confounders that we did adjust for.
5. Conclusions
In this biobank study, we found significantly lower urinary 6-SM levels in a large group of
stable RTRs compared to healthy controls. More importantly, low urinary 6-SM levels in RTRs were
independently associated with higher mortality risk, independent of potential confounders. Based
on these results, evaluation and management of melatonin metabolism could be considered for
improvement of long-term outcome in RTRs.
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